InventisBio licenses lung cancer drug D-0316 to Betta Pharma in RMB230m deal
In a significant development within the pharmaceutical industry, Shanghai-based InventisBio has entered into a strategic partnership with Betta…
Spectrum Pharmaceuticals seeks FDA approval for ROLONTIS to combat chemotherapy-induced neutropenia
In a significant move within the oncology sector, Spectrum Pharmaceuticals has submitted a Biologics License Application (BLA) to…
Teva launches generic version of Elidel Cream to expand eczema treatment options
Teva Pharmaceutical Industries has unveiled its generic version of Elidel (pimecrolimus) Cream, 1%, providing a more affordable treatment…
FDA accepts review of Kala Pharmaceuticals’ new dry eye treatment KPI-121 0.25%
The United States Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for KPI-121 0.25%,…
Vedanta Biosciences secures $27m to propel microbiome drug pipeline
US-based Vedanta Biosciences has raised $27 million in a Series C financing round to accelerate its pioneering work…
Lupin collaborates with AbbVie for $977m MALT1 inhibitor program targeting hematological cancers
Indian pharmaceutical company Lupin has entered a landmark agreement to out-license its MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation…
Novartis aims to strengthen cell therapy capabilities with CellforCure acquisition
Novartis has announced plans to acquire CellforCure, a French contract development and manufacturing organisation (CDMO), from LFB for…
Amgen submits BLA for Infliximab biosimilar ABP 710 to FDA
Amgen Inc. has officially submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA)…
Innovent Biologics and Incyte announce $391.5m partnership for cancer drugs in China
Innovent Biologics, a leading Chinese biopharma company, has struck a landmark deal with Incyte, a prominent US pharmaceutical…
Astellas Pharma acquires Potenza Therapeutics in $404.7m deal
Japanese pharmaceutical giant Astellas Pharma has announced the acquisition of US-based Potenza Therapeutics in a significant transaction valued…